9 January 2005 in Nature Structural & Molecular Biology
24 March 2016 in Orphanet Journal of Rare Diseases
Few studies have examined whether the healthcare needs of people living with rare diseases are being met. This study explores the experiences of Australian adults living with rare diseases in relation to diagnosis, information provision at the time of diagnosis, use of health and support services and involvement in research on their condition. The survey respondents are self-selected from the population of Australian residents aged 18 years and over who are living with a rare disease. An online survey was implemented between July-August 2014. Purposive snowballing sampling was used. The results are reported as percentages with significant differences between sub-groups assessed using chi-squared analyses. Eight hundred ten responses were obtained from adults living with a rare disease. 92.1 % had a confirmed diagnosis, of which 30.0 % waited five or more years for a diagnosis, 66.2 % had seen three or more doctors to get a diagnosis and 45.9 % had received at least one incorrect diagnosis. Almost three quarters (72.1 %) received no or not enough information at the time of diagnosis. In the 12 months prior to the survey, over 80 % of respondents had used the services of a general practitioner and a medical specialist while around a third had been inpatients at a hospital or had visited an emergency department. Only 15.4 % of respondents had ever used paediatric services, 52.8 % of these had experienced problems in the transition from paediatric to adult services. Only 20.3 % knew of a patient registry for their condition and 24.8 % were informed of clinical trials. These findings suggest that not all healthcare needs of people living with rare diseases are being met. Structural changes to Australian healthcare systems may be required to improve the integration and coordination of diagnosis and care. Health professionals may need greater awareness of rare diseases to improve the diagnostic process and support to meet the information requirements of people newly diagnosed with rare diseases. Health service use is likely higher than for the general population and further epidemiological studies are needed on the impact of rare diseases on the healthcare system.
1 August 2011 in Molecular Cell
1 January 2000 in Molecular Cell Biology Research Communications
5 January 2021 in RSC Chemical Biology
Using protein semi-synthesis, segmentally isotope-labelled variants of nucleosome-binding protein HMGN1 were generated with site-specific posttranslational modifications to explore their structural and functional effects.
26 November 2004 in European Journal of Immunology
GSGretchen T. F. Schwenger
Eosinophil infiltration of the lung is a feature of both allergic and nonallergic asthma, and IL‐5 is the key cytokine regulating the production and activation of these cells. Despite many studies focusing on the IL‐5 promoter in both humans and mice there is as yet no clear picture of how the IL‐5 gene is regulated. The aim of this study was to determine if distal regulatory elements contribute to appropriate regulation of the human IL‐5 (hIL‐5) gene. Activity of the –507/+44 hIL‐5 promoter was compared to expression of the endogenous IL‐5 gene in PER‐117 T cells. The IL‐5 promoter was not sufficient to reproduce a physiological pattern of IL‐5 expression. Further, functional analysis of the 5′ and 3′ intergenic regions revealed a number of novel regulatory elements. We have identified a conserved enhancer located approximately 6.2 kb upstream of the hIL‐5 gene. This region contains two potential GATA‐3‐binding sites and increases expression from the hIL‐5 promoter by up to ninefold.